RMC No. 7-2024 ends the VAT exemption for covered COVID-19 PPE, drugs, vaccines, and medical devices starting January 1, 2024.

Businesses selling or importing COVID-19-related personal protective equipment, drugs, vaccines, and medical devices must treat the covered transactions as subject to value-added tax starting January 1, 2024. RMC No. 7-2024 confirms that the temporary VAT exemption under Section 109(BB) of the National Internal Revenue Code, as amended by the CREATE Act and implemented under Revenue Regulations No. 4-2021, has reverted, meaning the covered sales and importations are no longer VAT-exempt.

What Changed Under RMC No. 7-2024

RMC No. 7-2024 announces the reversion of the VAT exemption previously granted to specific COVID-19-related transactions under Section 109(BB) of the Tax Code. The most important rule is direct: the listed transactions are no longer exempt from value-added tax effective January 1, 2024.

The affected transactions are the sale or importation of specific goods that were previously treated as VAT-exempt because of pandemic-related tax relief. These include capital equipment, spare parts, and raw materials necessary for the production of personal protective equipment components used for COVID-19 prevention. They also include drugs, vaccines, and medical devices specifically prescribed and directly used for the treatment of COVID-19. The VAT exemption also ends for drugs for the treatment of COVID-19 approved by the Food and Drug Administration for use in clinical trials, including raw materials directly necessary for the production of such drugs.

For businesses, this means that COVID-19 tax treatment can no longer be applied automatically to the listed goods. Companies that continued treating these transactions as VAT-exempt after January 1, 2024 should immediately review their invoices, importation entries, accounting treatment, tax returns, and pricing assumptions.

Who Is Affected by the VAT Reversion

The taxpayers most affected are sellers, importers, distributors, manufacturers, hospitals, medical suppliers, pharmaceutical companies, clinics, procurement groups, and businesses dealing in COVID-19-related medical goods. The change is especially important for VAT-registered companies that sell or import PPE-related goods, medical devices, vaccines, drugs for COVID-19 treatment, or raw materials used to manufacture those goods.

Corporate accountants and tax teams should pay close attention if their company previously relied on Section 109(BB) VAT exemption, RR No. 4-2021 COVID-19 VAT exemption rules, or BIR guidance on VAT-exempt COVID-19 medical supplies. The key search phrases for affected businesses are RMC 7-2024 VAT exemption, COVID-19 PPE VAT Philippines, VAT on medical devices Philippines, COVID-19 vaccines VAT exemption ended, and Section 109(BB) Tax Code VAT.

Transactions No Longer VAT-Exempt Beginning January 1, 2024

RMC No. 7-2024 specifically identifies three groups of transactions that are no longer VAT-exempt. First, the sale or importation of capital equipment, spare parts, and raw materials necessary for the production of personal protective equipment components is now subject to VAT. The covered PPE components include coveralls, gowns, surgical caps, surgical masks, N-95 masks, scrub suits, goggles and face shields, gloves, dedicated shoes, and shoe covers for COVID-19 prevention.

Second, the sale or importation of all drugs, vaccines, and medical devices specifically prescribed and directly used for the treatment of COVID-19 is now subject to VAT. This is particularly relevant to pharmaceutical companies, hospitals, clinics, drug distributors, and procurement departments that may have previously classified these transactions as VAT-exempt.

Third, the sale or importation of drugs for the treatment of COVID-19 approved by the Food and Drug Administration for use in clinical trials is now subject to VAT. The reversion also covers raw materials directly necessary for the production of such drugs. Businesses involved in clinical trial supply chains, drug development, pharmaceutical manufacturing, or medical research procurement should confirm whether their transactions fall within this category.

Effective Date and Compliance Deadline

The operational date that matters is January 1, 2024. From that date, the covered transactions are subject to VAT. RMC No. 7-2024 itself is dated January 11, 2024 and states that the circular takes effect immediately, but the VAT treatment reverts starting January 1, 2024.

This timing matters because some businesses may have issued invoices, booked transactions, or processed importations in early January 2024 using the prior VAT-exempt treatment. Accounting teams should review transactions from January 1, 2024 onward to determine whether VAT should have been imposed, reported, and remitted.

Penalties and Risk of Non-Compliance

RMC No. 7-2024 does not create a new special penalty for non-compliance. However, the practical tax risk is that a taxpayer who continues to treat covered sales or importations as VAT-exempt after January 1, 2024 may understate output VAT, incorrectly classify transactions, issue incorrect invoices, or file VAT returns that do not match the required treatment.

For VAT-registered taxpayers, the issue is not merely documentary. If VAT should have been imposed but was not properly accounted for, the taxpayer may face the ordinary consequences applicable to VAT non-compliance under the Tax Code and BIR audit procedures. Businesses should therefore avoid vague classifications such as medical supplies, COVID items, or exempt goods without verifying whether the item remains exempt under a separate Tax Code provision or special law.

Practical Steps for Businesses and Tax Teams

Companies should first identify all sales and importations from January 1, 2024 involving PPE production inputs, COVID-19 drugs, COVID-19 vaccines, COVID-19 medical devices, FDA-approved COVID-19 clinical trial drugs, and raw materials used to produce such drugs. The review should cover sales invoices, official receipts, purchase orders, importation documents, inventory records, ERP tax codes, and VAT return workpapers.

Second, businesses should update their invoicing and accounting systems so that the affected transactions are no longer tagged as VAT-exempt under Section 109(BB). For companies using automated tax codes, this may require coordination among accounting, IT, procurement, sales, and compliance teams.

Third, contracts and pricing arrangements should be reviewed. If prices were negotiated on the assumption that the transaction remained VAT-exempt, the parties should determine whether VAT is already included in the contract price or may be charged separately. This is especially important for long-term supply agreements, hospital procurement contracts, pharmaceutical distribution arrangements, and importation-based pricing.

Fourth, importers should coordinate with customs brokers and finance teams to ensure that VAT treatment is correctly applied at importation. The reversion affects both sale and importation of the covered goods, so businesses cannot limit their review to domestic sales alone.

Finally, companies should document their position. Where a product is no longer covered by the reverted exemption, the taxpayer should show that VAT was applied beginning January 1, 2024. Where a taxpayer believes a different exemption applies, that conclusion should be supported by a specific legal basis separate from the expired Section 109(BB) treatment.

ASG Law Can Help With BIR VAT Compliance

RMC No. 7-2024 is short, but its business impact is significant for companies that handled COVID-19 medical supplies, PPE inputs, drugs, vaccines, and medical devices. A small tax code error can affect pricing, billing, VAT returns, importation costs, and BIR audit exposure.

Ablola, Saribong & Gueco assists businesses, CFOs, accountants, importers, medical suppliers, and in-house counsel in reviewing VAT classifications, BIR compliance risks, invoicing practices, and tax audit exposure. For assistance with RMC No. 7-2024, VAT compliance, or BIR advisory work, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *